Vivani Medical, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam Mendelsohn
- Full Time Employees
- 37
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5858 Horton Street Alameda CA United States of America 94608
- IPO Date
- Nov 19, 2014
- CIK
- 0001266806
- Website
- vivani.com
- Similar Companies
- Business
- Vivani Medical, Inc. is a clinical-stage biopharmaceutical company dedicated to addressing chronic conditions with significant unmet medical needs. Leveraging its proprietary NanoPortal™ platform technology, the company develops a portfolio of miniature, subdermal drug implants designed to deliver sustained, consistent therapeutic levels of medication over extended periods, aiming to enhance patient adherence and tolerability. Its lead programs currently focus on GLP-1 receptor agonists, including semaglutide and exenatide implants, for chronic weight management, obesity, and type 2 diabetes, with the goal of once or twice-yearly administration. Furthermore, through its subsidiary Cortigent, which is in the process of spinning off into an independent entity, Vivani has advanced investigational visual prostheses systems, such as the Orion® system, aiming to restore useful artificial vision for individuals with profound blindness. The company is based in Alameda, California.
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Up 65.0% in March
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Gregg Williams Purchases 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
Vivani Medical, Inc. Announces Closing of Common Stock Offering
Insiders Are Buying These 3 Stocks Hand Over Fist
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off